Research and analysis

SARS-CoV-2 immunity-escape variants, 7 January 2021

Paper by academics on behalf of the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG).


SARS-CoV-2 immunity-escape variants - 7 January 2021

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


Paper prepared by academics for NERVTAG on viral evasion during antibody treatment of the new SARS-CoV 2 immunity-escape variants. It was considered at SAGE 75 on 7 January 2021.

The paper is the assessment of the evidence at the time of writing. As new evidence or data emerges, SAGE updates its advice accordingly.

This paper is a technical briefing which details how the new SARS-CoV-2 variant may react to antibody and immunisation treatment.

See more information on the new SARS-CoV-2 variant.

These documents are released as pre-print publications that have provided the government with rapid evidence during an emergency. These documents have not been peer-reviewed and there is no restriction on authors submitting and publishing this evidence in peer-reviewed journals.

Published 22 January 2021